Skip to main content
Annals of Translational Medicine logoLink to Annals of Translational Medicine
. 2022 Oct;10(19):1076. doi: 10.21037/atm-2022-34

Erratum to miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1

Editorial Office1
PMCID: PMC9622493  PMID: 36330407

This article (1) titled “miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1” (doi: 10.21037/atm-20-2081), unfortunately contains errors in Figure 5 and Figure S2. Two images were inadvertently misused in Figure 5D and Figure S2A. Overlapped images were found in the representative images of group “Ctrl” and “SR5” of Figure 5D. Besides, the images for group “SR5” of HepG2 invasion assay in Figure S1D and Figure S2A shared common areas. These mistakes happened during figure assembly. Since all the experiments have been repeated at least three times, these corrections do not change the description, interpretation, or the original conclusions of the manuscript. The corrected Figure 5 and Figure S2 can be found below.

Corrected Figure 5:

graphic file with name atm-10-19-1076-fig1.jpg

Corrected Figure S2:

graphic file with name atm-10-19-1076-fig2.jpg

The authors apologize for the oversight.

Click here to view the updated version of the article.

References

  • 1.Tan W, Lin Z, Chen X, et al. miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1. Ann Transl Med 2021;9:38. 10.21037/atm-20-2081 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Translational Medicine are provided here courtesy of AME Publications

RESOURCES